Taisuke Tobe

Kobe, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Efficacy and Safety of Enfortumab Vedotin by Trial Eligibility in Advanced Urothelial Carcinoma: A Multicenter Real-World Study.

Efficacy and Safety of Enfortumab Vedotin by Trial Eligibility in Advanced Urothelial Carcinoma: A Multicenter Real-World Study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: May 10, 2026

Comparison of effectiveness and safety of pembrolizumab plus lenvatinib versus nivolumab plus cabozantinib for metastatic renal cell carcinoma: a real-world study.

Comparison of effectiveness and safety of pembrolizumab plus lenvatinib versus nivolumab plus cabozantinib for metastatic renal cell carcinoma: a real-world study.

Journal: International journal of clinical oncology

Published: March 06, 2026

Prevalence and complementary distribution of FGFR3 alterations and ERBB2 amplification in metastatic urothelial carcinoma: a nationwide registry analysis.

Prevalence and complementary distribution of FGFR3 alterations and ERBB2 amplification in metastatic urothelial carcinoma: a nationwide registry analysis.

Journal: International journal of clinical oncology

Published: February 25, 2026

Real-World Safety and Early Effectiveness of First-Line Enfortumab Vedotin Plus Pembrolizumab with Routine Dexamethasone Premedication in Advanced Urothelial Carcinoma.

Real-World Safety and Early Effectiveness of First-Line Enfortumab Vedotin Plus Pembrolizumab with Routine Dexamethasone Premedication in Advanced Urothelial Carcinoma.

Journal: Cancers

Published: January 28, 2026

Risk stratification by pathological upstaging and tumor necrosis in clinical T1 clear-cell renal cell carcinoma: evidence from a multi-institutional cohort of 1081 patients.

Risk stratification by pathological upstaging and tumor necrosis in clinical T1 clear-cell renal cell carcinoma: evidence from a multi-institutional cohort of 1081 patients.

Journal: Japanese journal of clinical oncology

Published: December 02, 2025

Adequate Bacillus Calmette-Guérin maintenance therapy improves recurrence-free survival in high-risk non-muscle-invasive bladder cancer: A conditional survival study.

Adequate Bacillus Calmette-Guérin maintenance therapy improves recurrence-free survival in high-risk non-muscle-invasive bladder cancer: A conditional survival study.

Journal: Urologic oncology

Published: October 31, 2025

Pretreatment Voiding Volume as a Predictor of Post-brachytherapy Urinary Quality of Life in Patients With Prostate Cancer: A Retrospective Study.

Pretreatment Voiding Volume as a Predictor of Post-brachytherapy Urinary Quality of Life in Patients With Prostate Cancer: A Retrospective Study.

Journal: Cureus

Published: September 09, 2025

Evaluation of Preoperative Imaging Accuracy in Small cT3a Renal Cell Carcinoma.

Evaluation of Preoperative Imaging Accuracy in Small cT3a Renal Cell Carcinoma.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: June 16, 2025

Pathologic complete response to enfortumab vedotin plus pembrolizumab in node-positive urothelial carcinoma: a case report.

Pathologic complete response to enfortumab vedotin plus pembrolizumab in node-positive urothelial carcinoma: a case report.

Journal: International cancer conference journal

Published: May 10, 2025

Time to Oligoprogression From the Initiation of the Most Recent Systemic Treatment Is Associated With the Outcome of Progressive Site-Directed Therapy for Castration-Resistant Prostate Cancer.

Time to Oligoprogression From the Initiation of the Most Recent Systemic Treatment Is Associated With the Outcome of Progressive Site-Directed Therapy for Castration-Resistant Prostate Cancer.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: April 21, 2025

Risk stratification for recurrence after nephrectomy in high-risk renal cell carcinoma patients.

Risk stratification for recurrence after nephrectomy in high-risk renal cell carcinoma patients.

Journal: International journal of clinical oncology

Published: April 20, 2025

Efficacy and safety of routine corticosteroid premedication in enfortumab vedotin therapy for advanced urothelial carcinoma.

Efficacy and safety of routine corticosteroid premedication in enfortumab vedotin therapy for advanced urothelial carcinoma.

Journal: International urology and nephrology

Published: February 20, 2025

Showing 1-12 of 20

Last Updated: 09/26/2026